313 related articles for article (PubMed ID: 36356599)
41. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
42. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
43. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
44. TCR validation toward gene therapy for cancer.
Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
[TBL] [Abstract][Full Text] [Related]
45. Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells.
Paria BC; Levin N; Lowery FJ; Pasetto A; Deniger DC; Parkhurst MR; Yossef R; Kim SP; Florentin M; Ngo LT; Ray S; Krishna S; Robbins PF; Rosenberg SA
J Immunother; 2021 Jan; 44(1):1-8. PubMed ID: 33086340
[TBL] [Abstract][Full Text] [Related]
46. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.
Kobayashi E; Mizukoshi E; Kishi H; Ozawa T; Hamana H; Nagai T; Nakagawa H; Jin A; Kaneko S; Muraguchi A
Nat Med; 2013 Nov; 19(11):1542-6. PubMed ID: 24121927
[TBL] [Abstract][Full Text] [Related]
47. Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Bianchi V; Harari A; Coukos G
Front Immunol; 2020; 11():1215. PubMed ID: 32695101
[TBL] [Abstract][Full Text] [Related]
48. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
49. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
50. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
51. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
52. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
53. Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy.
Camperi J; Devarajan S; McKay A; Tarighat S; Chen D; Hu Z
J Immunol Methods; 2023 Jun; 517():113491. PubMed ID: 37187316
[TBL] [Abstract][Full Text] [Related]
54. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
55. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
56. Identification of NY-ESO-1
Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
Front Immunol; 2021; 12():644520. PubMed ID: 33833762
[TBL] [Abstract][Full Text] [Related]
57. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
[TBL] [Abstract][Full Text] [Related]
58. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
59. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.
Ivanov R; Hol S; Aarts TI; Hagenbeek A; Ebeling SB
Clin Exp Immunol; 2006 Jan; 143(1):78-84. PubMed ID: 16367937
[TBL] [Abstract][Full Text] [Related]
60. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
